After dipping a toe back in the patent eligibility waters, the U.S. Supreme Court has decided against diving all the way back in.
The justices denied certiorari Monday in two cases in which the court had sought the views of the solicitor general, HP v. Berkheimer and Hikma Pharmaceuticals USA v. Vanda Pharmaceuticals. Either case could have forced the court to reconsider a quartet of Section 101 cases that have tilted the law of patent eligibility away from patent owners and more toward accused infringers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]